Jane Huang - Oct 4, 2025 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
President, CMO
Signature
/s/ Bryant D. Lim, Attorney-in-Fact
Stock symbol
PRLD
Transactions as of
Oct 4, 2025
Transactions value $
-$4,932
Form type
4
Date filed
10/7/2025, 07:05 AM
Previous filing
Jul 8, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Huang Jane President, CMO C/O PRELUDE THERAPEUTICS INCORPORATED, 175 INNOVATION BOULEVARD, WILMINGTON /s/ Bryant D. Lim, Attorney-in-Fact 2025-10-07 0001683913

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRLD Common Stock Options Exercise +9.38K +11.59% 90.3K Oct 4, 2025 Direct F1
transaction PRLD Common Stock Tax liability -$4.93K -3.36K -3.72% $1.47 86.9K Oct 4, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Restricted Stock Unit Options Exercise $0 -9.38K -33.33% $0.00 18.8K Oct 4, 2025 Common Stock 9.38K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.
F2 Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs.
F3 The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.